DIPSS Plus Score for Prognosis in Myelofibrosis
Estimate prognosis in myelofibrosis.
The DIPSS was proposed and validated by Passamonti et al to estimate prognosis in myelofibrosis.
The DIPSS plus score further refines the prior prognostic scoring system with the addition of DIPSS-independent risk factors, including karyotype, transfusion dependency and platelet count. The score was developed and validated by Gangat et al.
Prognosis based on 6 point scoring system:
- If score is 0: Patient is considered "low risk" according to the DIPSS plus system. Median survival is estimated to be 180 months
- If score is 1: Patient is considered "intermediate-1 risk" according to the DIPSS plus system. Median survival is estimated to be 80 months
- If score is 2-3: Patient is considered "intermediate-2 risk" according to the DIPSS plus system. Median survival is estimated to be 35 months
- If score is 4 or more: Patient is considered "high risk" according to the DIPSS plus system. Median survival is estimated to be 16 months
- [1]Gangat et al.: DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011 February 1, 29 (4): 392-7
- [2]Passamonti et al.: A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).Blood 2010 March 4, 115 (9): 1703-8
Results
Real-time automated computation
The DIPSS was proposed and validated by Passamonti et al to estimate prognosis in myelofibrosis.
The DIPSS plus score further refines the prior prognostic scoring system with the addition of DIPSS-independent risk factors, including karyotype, transfusion dependency and platelet count. The score was developed and validated by Gangat et al.
Prognosis based on 6 point scoring system:
- If score is 0: Patient is considered "low risk" according to the DIPSS plus system. Median survival is estimated to be 180 months
- If score is 1: Patient is considered "intermediate-1 risk" according to the DIPSS plus system. Median survival is estimated to be 80 months
- If score is 2-3: Patient is considered "intermediate-2 risk" according to the DIPSS plus system. Median survival is estimated to be 35 months
- If score is 4 or more: Patient is considered "high risk" according to the DIPSS plus system. Median survival is estimated to be 16 months
- [1]Gangat et al.: DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011 February 1, 29 (4): 392-7
- [2]Passamonti et al.: A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).Blood 2010 March 4, 115 (9): 1703-8